Publications| ICECaP

ICECaP Adjuvant

ICECaP Working Group. (2015) ‘The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP)’ Journal of the National Cancer Institute 107:12
DOI:10.1093/jnci/djv261
Xie, W, Regan, MM, Buyse, M, Halabi, S, Kantoff, PW, Sartor, O, Soule, H, Clarke, NW, Collette, L, Dignam, JJ, Fizazi, K, Paruleker, WR, Sandler, HM, Sydes, MR, Tombal, B, Williams, SG, Sweeney, CJ and on behalf of the ICECaP Working Group (2017) ‘Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer’ Journal of Clinical Oncology 35:27, 3097-3104
DOI: 10.1200/JCO.2017.73.9987
Sweeney, C. (2018) ‘Having Found Meaningful Intermediate Prostate Cancer Clinical Endpoints Associated with Overall Survival, What Next?’ European Urology 74:4, 420-421
DOI: 10.1016/j.eururo.2018.06.036
Xie, W, Halabi, S, Tierney, JF, Sydes, MR, Collette, L, Dignam, JJ, Buyse, M, Sweeney, CJ, Regan, MM (2019) ‘A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses’ JNCI Cancer Spectrum 3:1 pkz002
DOI: 10.1093/jncics/pkz002
Xie, W, Regan, MM, Buyse, M, Halabi, S, Kantoff, PW, Sartor, O, Soule, H, Berry, D, Clarke, N, Collette, L, De Abreu Lourenco, R, Dignam, M, Eisenberger, M, James, N, Fizazi, K, Gillessen, S, Loriot, Y, Mottet, N, Parulekar, W, Sandler, H, Spratt, D, Sydes, M, Tombal, B, Williams, S & Sweeney, CJ and on behalf of the ICECaP Working Group (2020) ‘Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation’ Journal of Clinical Oncology 38:26, 3032-3041
DOI: 10.1200/JCO.19.03114
Marc Buyse, Everardo D Saad, Tomasz Burzykowski, Meredith M Regan, Christopher S Sweeney, Surrogacy Beyond Prognosis: The Importance of “Trial-Level” Surrogacy, The Oncologist, Volume 27, Issue 4, April 2022, Pages 266–271, DOI: 10.1093/oncolo/oyac006

STOPCAP

Vale, CL, Burdett, S, Rydzewska, LH, Albiges, L, Clarke, NW, Fisher, D, Fizazi, K, Gravis, G, James, ND, Mason, MD, Parmar, MK, Sweeney, C.J, Sydes, MR, Tombal, B, Tierney, JF, the STOpCaP Steering Group (2016). Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncology 17: 2, 243-256
DOI: 10.1016/S1470-2045(15)00489-1
Rydzewska, LHM, Burdett, S, Vale, CL, Clarke, NW, Fizazi, K, Kheoh, T, Mason, MD, Miladinovic, B, James, ND, Parmar, MKB, Spears, MR, Sweeney, CJ, Sydes, MR, Tran, N, Tierney, JF, the STOPCaP Abiraterone Collaborators (2017). Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. European Journal of Cancer 84: 88-101
DOI: 10.1016/j.ejca.2017.07.003
Vale, CL, Fisher, DJ, White, IR, Carpenter, J, Burdett, S, Clarke, NW, Fizazi,, K, Gravis, G, James, ND, Mason, MD, Parmar, MKB, Rydzewska, LH, Sweeney, C.J, Spears, MR, Sydes, MR, Tierney, JF (2018). What is the optimal systemic treatment for men with metastatic, hormone- naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Annals of Oncology 29: 5, 1249-1257
DOI: 10.1093/annonc/mdy071
Tierney, JF, Vale, CL, Parelukar, WR, Rydzewska, L, Halabi, S (2019) Evidence synthesis to accelerate and improve the evaluation of therapies for metastatic hormone-sensitive prostate cancer. European Urology Focus 5: 2, 137-143.
DOI: 10.1016/j.euf.2019.01.005 (abstract only)
Burdett, S, Boeve, LM, Ingleby, FC, Fisher, DJ, Rydzewska, LH, Vale, CL, van Andel, G, Clarke, NW, Hulshof, M, James, ND, Parker, CC, Parmar, MK, Sweeney, CJ, Sydes, MR, Tombal, B, Verhagen, PCMS, Tierney, JF, the STOPCAP M1 Radiotherapy Collaborators (2019). Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis. European Urology 76: 1,115-124
DOI: 10.1016/j.eururo.2019.02.003

ICECaP Publications

ICECaP Adjuvant

STOPCAP